Cite
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO‐SOR study.
MLA
Carballo, Folgoso, Lorena, et al. “Evaluation of Cardiovascular Events in Patients with Hepatocellular Carcinoma Treated with Sorafenib in the Clinical Practice. The CARDIO‐SOR Study.” Liver International, vol. 41, no. 9, Sept. 2021, pp. 2200–11. EBSCOhost, https://doi.org/10.1111/liv.14941.
APA
Carballo, F. L., Álvarez, V. R., Lorca, R., Castaño, G. A., Cuevas, J., González, D. M. L., Martín, M., Álvarez, N. C., Cadahía, V., Morís, C., Rodríguez, M., & Varela, M. (2021). Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO‐SOR study. Liver International, 41(9), 2200–2211. https://doi.org/10.1111/liv.14941
Chicago
Carballo, Folgoso, Lorena, Velasco, Rut Álvarez, Rebeca Lorca, García, Andrés Castaño, Javier Cuevas, Diéguez, María Luisa González, María Martín, et al. 2021. “Evaluation of Cardiovascular Events in Patients with Hepatocellular Carcinoma Treated with Sorafenib in the Clinical Practice. The CARDIO‐SOR Study.” Liver International 41 (9): 2200–2211. doi:10.1111/liv.14941.